Odyssey Logistics & Technology Posts Eight Percent Growth; Continues fourteen year trend of consecutive growth
02.02.17
Danbury, Conn. (Feb. 2, 2017) — Odyssey Logistics & Technology Corporation (Odyssey) announced today that it has posted fourteen consecutive years of growth, with net revenue up eight percent in 2016. The company attributes this year’s results to sustaining its leadership position in complex key markets, implementing operational efficiencies and maximizing benefits from the acquisition of Linden Bulk Transportation. Read Full Release
BMP Invests in COTA
12.20.16
Boston Millennia Partners Invests in Cota, Inc. Boston, MA, December 2016, Boston Millennia Partners is pleased to announce its investment in Cota, Inc. as part of an $18 million growth equity round. Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification system to assess patient results on specific treatment protocols. Cota’s customers include pharmaceutical companies, healthcare providers and insurance companies. The company has partnerships with several major pharmaceutical companies in the U.S. including Novartis and Celgene, and with data provider Foundation Medicine. The company has received strategic investments from Novartis, Celgene, Foundation Medicine and Horizon Healthcare. Read Full Release
Jeffries Key Takeaway: Another Formulary Win Further Positions Xtampza for a Potential 1H17 Inflection
12.15.16
COLL announced another formulary “win” for Xtampza following successful contracting with ESRX, the largest US pharmacy benefits manager (PBM). Starting January 1, 2017, Xtampza will be added to ESRX’s formulary as a preferred brand with access to another 28M commercial lives. Based on steady progress with the launch and managed care wins, we continue to believe that Xtampza Rxs are positioned for an inflection in 1H17 and see the drug as a $400M+ peak product. Read Full Release
Report of the Cancer Moonshot Task Force
10.17.16
While bold, the goal of the Cancer Moonshot is within our grasp. Today, society has the benefit of decades of scientific understanding and vast amounts of rich data just waiting to be transformed into solutions. We now know that cancer is hundreds of diseases, largely of our genome, and we have developed new and innovative ways of capitalizing on this knowledge. We know that our behavior and environment contribute to our likelihood of getting cancer, and we are modifying our behaviors and exposures to avoid known risks. We know that prevention and early diagnosis are key to fighting cancer, and we can build these efforts into clinical care. Read Full Release
MedAptus Hospitalist Customers Leverage Real-Time Data to Manage Patient Risk
10.20.16
MedAptus® today announced the availability of real-time analytics, the Hospitalist Risk Series, that leverage patient history and admission activity to identify those at greatest risk for re-admissions, and also helps providers better manage resources related to length of stay. The new Series, aimed primarily at hospitalists on the front line of acute patient care, is available through the MedAptus Professional Charge Capture (Pro) suite. This latest offering extends the Pro solution’s ability to compute data from admission/discharge feeds and diagnosis history in order to meaningfully impact key metrics around hospitalizations that hospital medicine providers are increasingly responsible for. Read Full Release
Despite Recent Performance We Still See Room for Upside Given United Win and Xtampza ER Tailwinds for 2017
10.03.16
Following recent share performance that has shares almost doubling in the past two weeks, we continue to see room for share appreciation as the Xtampza ER launch has clear tailwinds as we exit the summer through 2017. Management has signed at least one large managed care win with UnitedHealth (UNH $140.00) and we believe additional managed care wins are likely during the fourth quarter as well as the potential for comparative data between OxyContin and Xtampza ER being added to label. Admittedly, the Xtampza ER launch was slow as management chose to launch during the summer months despite the historically slow season, which was compounded by a lack of approved marketing materials. However, the company recently received approved marketing materials and given formulary wins (both UnitedHealth and likely additional wins), we should see a ramping up of scripts over the next quarter and into 2017. Read Full Release
Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
09.29.16
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER),” in the peer-reviewed medical journal, The Journal of Clinical Pharmacology. The publication presents the results from a human abuse potential (HAP) study, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of intact Xtampza® ER (oxycodone extended-release), oral administration of chewed Xtampza ER, and oral administration of crushed immediate-release oxycodone in non-dependent, recreational drug abusers. Read Full Release
Collegium CEO Michael Heffernan Named EY Entrepreneur of the Year
06.27.16
CANTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EY announced that Collegium’s CEO, Michael Heffernan, received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare category in New England. This year marks the 30th anniversary of the EY Entrepreneur of the Year Award program. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities. Winners were selected by an independent panel of judges, and the award was presented at a special gala event at the Marriott Copley Place on June 23, 2016. Read Full Release
Collegium Receives FDA Approval for Xtampza™ ER
04.26.16
CANTON, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) approved Xtampza™ ER (oxycodone) extended-release (ER) capsules CII, a twice-daily, oxycodone medication for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Read Full Release
Bivarus Raises $2 Million to Fuel Expansion Following Strong Growth in 2015
03.19.16
DURHAM, N.C. (Business Wire) March, 2016 – Bivarus, a patient-centered analytics company working with healthcare organizations to measure and analyze the patient experience, announced today it raised $2 million in its oversubscribed round of funding. This latest financing was co-led by new investor Hatteras Venture Partners and existing investor Excelerate Health Ventures. In addition to local investors, Bivarus attracted new institutional investors from outside of the Raleigh/Durham region: NueCura Partners of Nashville, Tenn., and Boston Millennia Partners of Boston, Mass. Read Full Release
Collegium Announces Publication of Data on the In Vitro Assessment of IV Abuse of Xtampza ER in Journal of Opioid Management
03.03.16
CANTON, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from a laboratory-based extraction, injection and syringeability study for Xtampza® ER compared to other marketed opioid analgesics in peer-reviewed Journal of Opioid Management. The publication is titled, “In Vitro Assessment of the Potential for Abuse via the Intravenous Route of Oxycodone DETERx® Microspheres.” Read Full Release
William Blair Initial Report on Collegium
02.19.16
Initiating Coverage With an Outperform Rating and $35 Price Target Read Full Release
Odyssey Logistics & Technology Posts Earnings Growth of 18 Percent
02.09.16
Danbury, Conn. (Feb. 9, 2016) — Odyssey Logistics & Technology Corporation (Odyssey) announced today that earnings grew 18 percent in 2015, continuing an eight year trend of consecutive double digit earnings growth. Holding a leadership position in complex verticals, with a focus on driving significant technology advancements and realizing operational efficiencies, has facilitated this growth. Read Full Release
BMP Portfolio Company Collegium Announces Favorable Judgment by the District Court of Massachusetts
02.11.16
CANTON, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the District Court of Massachusetts issued an order for final judgment in favor of Collegium and against plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., and Rhodes Technologies. The judgment relates to Purdue’s three Orange Book-listed patents asserted against Collegium that were the cause of the 30 month stay imposed on our New Drug Application for Xtampza™ ER... Read Full Release
Millennia Portfolio Company, MedAptus®, Announces Emerson Hospital Deploys MedAptus to Improve Charge Capture, Management Processes
10.27.15
MedAptus® announces Emerson Hospital has selected the company’s Pro Charge Capture technology for its inpatient medicine, pediatrics and behavioral health providers. These clinical end-users utilize the Pro solution while on rounds at both Emerson and Spaulding Rehabilitation Hospitals. Read Full Release
Boston Millennia Partners Expands Venture Affiliate Program
10.15.15
Ed, Jeremy and Jim join the other distinguished members of our Venture Affiliate Program (VAP). The VAP supports the firm's business objectives, including deal sourcing and portfolio company support, and is comprised of senior executives who have had extensive relevant business and investing experience. Read Full Release
Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain
11.09.15
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announces that the United States Food and Drug Administration (FDA) has granted tentative approval to the Company's New Drug Application (NDA) for Xtampza™ ER (oxycodone) extended-release capsules. Read Full Release
Histogenics Corporation to Participate in Upcoming Scientific and Investor Conferences
10.01.15
WALTHAM, Mass., October 1, 2015 /GLOBE NEWSWIRE/ – Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be participating in four upcoming conferences. Read Full Release
Millennia Founders Fund Invests in Avhana Health
06.30.15
Boston Millennia's Founders Fund invests in the seed round of Avhana Health, a Maryland-based startup with a mission of developing the world's most robust clinical decision support platform. Read Full Release
Liquidity Events Take Center Stage for Boston Millennia Partners Funds
03.03.15
2014 developed as a year of favorable exit events for several companies in the Boston Millennia Partners portfolio. We look back on the year and highlight the portfolio companies, CardioMEMS, Inc. Precision Dermatology, Inc. and PHT which produced over $130 million in cash returns for our partnerships. Read Full Release